Analytical Data
-
Gene name
OPRD1
- Application
-
Alternative Names
OPRD1；OPRD；Delta-type opioid receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41143
-
Expression Region
1-372aa
-
AA Sequence
MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTACTPSDGPGGGAAA
-
Molecular Weight
41.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OPRD1, or opioid receptor delta 1, is a member of the opioid receptor family, which plays a crucial role in pain modulation, emotional response, and various neurobiological processes. Traditionally known for its significance in the central nervous system, OPRD1 has garnered interest due to its potential therapeutic applications in treating pain and addiction-related disorders. Research on the recombinant OPRD1 protein has accelerated in recent years, enabling scientists to better understand its signaling mechanisms and ligand-binding properties. The ability to produce recombinant OPRD1 facilitates high-throughput screening of potential drug candidates, expanding the possibilities for novel analgesics that could minimize side effects commonly associated with conventional opioids. Moreover, insights from OPRD1 studies may lead to the development of targeted therapies that can modulate the receptor's function without the addictive properties of other opioids. As the global opioid crisis continues to present significant public health challenges, the exploration of OPRD1 and its pathways represents a crucial avenue toward discovering new treatment strategies aimed at alleviating pain and combating addiction while maintaining safety and efficacy. This ongoing research not only enhances our understanding of the receptor's biological roles but also holds promise for innovative pharmacological interventions in the future.
